ArticleJournal of molecular histology2025
YTHDF3-associated m6A regulation and cuproptosis-related gene expression in steroid-induced osteonecrosis of the femoral head.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FTO in Bone Diseases: Functions, Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
- Advances in Research on Autophagy in Steroid-Induced Osteonecrosis of the Femoral Head: Dual Regulation of Its Beneficial and Detrimental Effects.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the role of N6-methyladenosine (m6A) RNA modification in regulating Cuproptosis in steroid-induced osteonecrosis of the femoral head (SONFH), providing insights into its underlying mechanisms and therapeutic targets. Gene expression profiles from both human (GSE123568; 30 SONFH patients and 10 controls) and rat femoral head samples (GSE26316; 3 SONFH and 3 controls) were analyzed to identify differentially expressed genes (DEGs) and enriched pathways. In a matched case-control study, femoral head tissues from SONFH patients and non-SONFH controls were collected. The expression of YTH N6-methyladenosine RNA binding protein 3 (YTHDF3) and dihydrolipoamide dehydrogenase (DLD) was measured using qRT-PCR and Western blotting. Functional validation was performed in human bone marrow mesenchymal stem cells (BMSCs) via siRNA-mediated knockdown of YTHDF3 and treatment with elesclomol, a cuproptosis inducer. In the GSE26316 and GSE123568 datasets, we identified 708 common DEGs. Cuproptosis were activated in SONFH. The expression levels of YTHDF3 and DLD were elevated in SONFH tissues. Knockdown of YTHDF3 reduced the DLD expression and mitigated the inhibitory effects of elesclomol on BMSC proliferation and osteogenesis. YTHDF3 may contribute to SONFH progression by regulating DLD expression and cuproptosis, offering a potential important molecular target for novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.